New 'suicide' molecule halts rheumatoid arthritis
Researcher invents nontoxic drug that forces hyperactive immune cells to die
A researcher from Northwestern University Feinberg School of medicine has invented a novel way to halt and even reverse rheumatoid arthritis. He developed an imitation of a suicide molecule that floats undetected into overactive immune cells responsible for the disease. Whimsically referred to as Casper the Ghost, the stealthy molecule causes the immune cells to self-destruct. The approach, tested on mice, doesn't carry the health risks of current treatments. The study will be published in arthritis & Rheumatism.
"This new therapy stopped the disease cold in 75 percent of the mice," reported Harris Perlman, the lead author and an associate professor of medicine at Feinberg. "The best part was we didn't see any toxicity. This has a lot of potential for creating an entirely new treatment for rheumatoid arthritis."
Healthy immune cells are supposed to die after they attack an invading virus or bacteria. But in rheumatoid arthritis, the immune cells called macrophages live and go rogue. They proliferate in the blood, build up in the joints and invade cartilage and bone. Currently, there is no effective, nontoxic way to stop them.
Perlman discovered that immune cells in rheumatoid arthritis are low in a critical molecule called Bim, whose job is to order the cells to self-destruct. To correct that shortage, Perlman developed an imitation of the molecule, called BH3 mimetic. When Harris injected his drug into mice with rheumatoid arthritis, it floated ghostlike into their macrophages and bam!, the misbehaving immune cells self destructed.
In his research, Harris showed the molecule could prevent the development of rheumatoid arthritis as well as trigger a remission of existing disease. After the drug was injected in animals with the disease, joint swelling was reduced and bone destruction decreased.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
